Marina Biotech Advances FAP Drug into Phase I

The move marks the company's foray into the ranks of clinical-stage drug developers and its first steps toward becoming a therapeutics marketer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.